Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9

Kidney International

Volumn 67, Issue 5, 2005, Pages 1907-1912

  Passauer, Jens ^a   Pistrosch, Frank ^b   Lässig, Grit ^b   Herbrig, Kay ^b   Büssemaker, Eckhart ^b   Gross, Peter ^b   Fleming, Ingrid ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NONE

Author keywords

Endothelium derived hyperpolarizing factor; Nitric oxide; Plethysmography; Sulfaphenazole

Indexed keywords

ACETYLCHOLINE; CYTOCHROME P450 2C9; EPOXYICOSATRIENOIC ACID; FREE RADICAL; IBUPROFEN; JENAPROFEN; MIOCHOL E; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; SULFAPHENAZOLE;

ADULT; ARTERY ENDOTHELIUM; ARTERY MUSCLE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FOREARM BLOOD FLOW; HEMODIALYSIS; HUMAN; HYPERPOLARIZATION; MALE; MUSCLE TONE; PRIORITY JOURNAL; UREMIA; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 17744378374     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00289.x     Document Type: Article

References (22)

1. ROSS R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115-126, 1999
2. PERTICONE F, CERAVOLO R, PUJIA A, et al: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104:191-196, 2001
3. HALCOX JP, SCHENKE WH, ZALOS G, et al: Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653-658, 2002
4. FOLEY RN, PARFREY PS, SARNAK MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-S23, 1998
5. KARI JA, DONALD AE, VALLANCE DT, et al: Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 52:468-472, 1997
6. JOANNIDES R, BAKKALI E, LE ROY F, et al: Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 12:2623-2628, 1997
7. PASSAUER J, BUSSEMAKER E, RANGE U, et al: Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 11:1726-1734, 2000
8. BUSSE R, EDWARDS G, FELETOU M, et al: EDHF: Bringing the concepts together. Trends Pharmacol Sci 23:374-380, 2002
9. FISSLTHALER B, POPP R, KISS L, et al: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401:493-497, 1999
10. ARCHER SL, GRAGASIN FS, WU X, et al: Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 107:769-776, 2003
11. FLEMING I, MICHAELIS UR, BREDENKOTTER D, et al: Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88:44-51, 2001
12. FICHTLSCHERER S, DIMMELER S, BREUER S, et al: Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109:178-183, 2004
13. MORRIS ST, MCMURRAY JJ, RODGER RS, JARDINE AG: Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant 15:1194-1200, 2000
14. CARLSSON I, WENNMALM A: Effect of different prostaglandin synthesis inhibitors on post-occlusive blood flow in human forearm. Prostaglandlns 26:241-252, 1983
15. DAWES M, CHOWIENCZYK PJ, RITTER JM: Quantitative aspects of the inhibition by N(G)-monomethyl-L-arginine of responses to endothelium-dependent vasodilators in human forearm vasculature. Br J Pharmacol 134:939-944, 2001
16. MANCY A, DIJOLS S, POLI S, et al: Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 35:16205-16212, 1996
17. PASSAUER J, BUSSEMAKER E, LASSIG G, et al: Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin Sci (Lond) 105:513-518, 2003
18. HILLIG T, KRUSTRUP P, FLEMING I, et al: Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol 546:307-314, 2003
19. ITABE H, YAMAMOTO H, IMANAKA T, et al: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37:45-53, 1996
20. ANNUK M, ZILMER M, LIND L, et al: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747-2752, 2001
21. CROSS JM, DONALD AE, NUTTALL SL, et al: Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 63:1433-1442, 2003
22. QUILLEY J, FULTON D. MCGIFF JC: Hyperpolarizing factors. Biochem Pharmacol 54:1059-1070, 1997